The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Follicular Lymphoma Treatment Market Research Report 2024
Synopsis
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The global Follicular Lymphoma Treatment market was valued at US$ 1711.1 million in 2023 and is anticipated to reach US$ 2203.2 million by 2030, witnessing a CAGR of 3.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Treatment.
Report Scope
The Follicular Lymphoma Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Follicular Lymphoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Follicular Lymphoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
Segment by Type
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Follicular Lymphoma Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The global Follicular Lymphoma Treatment market was valued at US$ 1711.1 million in 2023 and is anticipated to reach US$ 2203.2 million by 2030, witnessing a CAGR of 3.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Treatment.
Report Scope
The Follicular Lymphoma Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Follicular Lymphoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Follicular Lymphoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
Segment by Type
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Follicular Lymphoma Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Follicular Lymphoma Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Radiotherapy
1.2.4 Monoclonal Antibodies
1.2.5 Stem Cell Transplantation
1.3 Market by Application
1.3.1 Global Follicular Lymphoma Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Follicular Lymphoma Treatment Market Perspective (2019-2030)
2.2 Follicular Lymphoma Treatment Growth Trends by Region
2.2.1 Global Follicular Lymphoma Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Follicular Lymphoma Treatment Historic Market Size by Region (2019-2024)
2.2.3 Follicular Lymphoma Treatment Forecasted Market Size by Region (2025-2030)
2.3 Follicular Lymphoma Treatment Market Dynamics
2.3.1 Follicular Lymphoma Treatment Industry Trends
2.3.2 Follicular Lymphoma Treatment Market Drivers
2.3.3 Follicular Lymphoma Treatment Market Challenges
2.3.4 Follicular Lymphoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Follicular Lymphoma Treatment Players by Revenue
3.1.1 Global Top Follicular Lymphoma Treatment Players by Revenue (2019-2024)
3.1.2 Global Follicular Lymphoma Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Follicular Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Follicular Lymphoma Treatment Revenue
3.4 Global Follicular Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Follicular Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Treatment Revenue in 2023
3.5 Follicular Lymphoma Treatment Key Players Head office and Area Served
3.6 Key Players Follicular Lymphoma Treatment Product Solution and Service
3.7 Date of Enter into Follicular Lymphoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Follicular Lymphoma Treatment Breakdown Data by Type
4.1 Global Follicular Lymphoma Treatment Historic Market Size by Type (2019-2024)
4.2 Global Follicular Lymphoma Treatment Forecasted Market Size by Type (2025-2030)
5 Follicular Lymphoma Treatment Breakdown Data by Application
5.1 Global Follicular Lymphoma Treatment Historic Market Size by Application (2019-2024)
5.2 Global Follicular Lymphoma Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Follicular Lymphoma Treatment Market Size (2019-2030)
6.2 North America Follicular Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Follicular Lymphoma Treatment Market Size by Country (2019-2024)
6.4 North America Follicular Lymphoma Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Follicular Lymphoma Treatment Market Size (2019-2030)
7.2 Europe Follicular Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Follicular Lymphoma Treatment Market Size by Country (2019-2024)
7.4 Europe Follicular Lymphoma Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Follicular Lymphoma Treatment Market Size (2019-2030)
8.2 Asia-Pacific Follicular Lymphoma Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Follicular Lymphoma Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Follicular Lymphoma Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Follicular Lymphoma Treatment Market Size (2019-2030)
9.2 Latin America Follicular Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Follicular Lymphoma Treatment Market Size by Country (2019-2024)
9.4 Latin America Follicular Lymphoma Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Follicular Lymphoma Treatment Market Size (2019-2030)
10.2 Middle East & Africa Follicular Lymphoma Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Follicular Lymphoma Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Follicular Lymphoma Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Detail
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Detail
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Detail
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Follicular Lymphoma Treatment Introduction
11.3.4 Celgene Corporation Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.3.5 Celgene Corporation Recent Development
11.4 Celldex Therapeutics, Inc.
11.4.1 Celldex Therapeutics, Inc. Company Detail
11.4.2 Celldex Therapeutics, Inc. Business Overview
11.4.3 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Introduction
11.4.4 Celldex Therapeutics, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.4.5 Celldex Therapeutics, Inc. Recent Development
11.5 Celltrion, Inc.
11.5.1 Celltrion, Inc. Company Detail
11.5.2 Celltrion, Inc. Business Overview
11.5.3 Celltrion, Inc. Follicular Lymphoma Treatment Introduction
11.5.4 Celltrion, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.5.5 Celltrion, Inc. Recent Development
11.6 Cellular Biomedicine Group, Inc.
11.6.1 Cellular Biomedicine Group, Inc. Company Detail
11.6.2 Cellular Biomedicine Group, Inc. Business Overview
11.6.3 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Introduction
11.6.4 Cellular Biomedicine Group, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.6.5 Cellular Biomedicine Group, Inc. Recent Development
11.7 Coherus BioSciences, Inc.
11.7.1 Coherus BioSciences, Inc. Company Detail
11.7.2 Coherus BioSciences, Inc. Business Overview
11.7.3 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Introduction
11.7.4 Coherus BioSciences, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.7.5 Coherus BioSciences, Inc. Recent Development
11.8 CTI BioPharma Corp.
11.8.1 CTI BioPharma Corp. Company Detail
11.8.2 CTI BioPharma Corp. Business Overview
11.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Introduction
11.8.4 CTI BioPharma Corp. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.8.5 CTI BioPharma Corp. Recent Development
11.9 Curis, Inc.
11.9.1 Curis, Inc. Company Detail
11.9.2 Curis, Inc. Business Overview
11.9.3 Curis, Inc. Follicular Lymphoma Treatment Introduction
11.9.4 Curis, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.9.5 Curis, Inc. Recent Development
11.10 Dynavax Technologies Corporation
11.10.1 Dynavax Technologies Corporation Company Detail
11.10.2 Dynavax Technologies Corporation Business Overview
11.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Introduction
11.10.4 Dynavax Technologies Corporation Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.10.5 Dynavax Technologies Corporation Recent Development
11.11 Eisai
11.11.1 Eisai Company Detail
11.11.2 Eisai Business Overview
11.11.3 Eisai Follicular Lymphoma Treatment Introduction
11.11.4 Eisai Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.11.5 Eisai Recent Development
11.12 EpiZyme, Inc.
11.12.1 EpiZyme, Inc. Company Detail
11.12.2 EpiZyme, Inc. Business Overview
11.12.3 EpiZyme, Inc. Follicular Lymphoma Treatment Introduction
11.12.4 EpiZyme, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.12.5 EpiZyme, Inc. Recent Development
11.13 F. Hoffmann-La Roche Ltd.
11.13.1 F. Hoffmann-La Roche Ltd. Company Detail
11.13.2 F. Hoffmann-La Roche Ltd. Business Overview
11.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Introduction
11.13.4 F. Hoffmann-La Roche Ltd. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.13.5 F. Hoffmann-La Roche Ltd. Recent Development
11.14 Genentech, Inc.
11.14.1 Genentech, Inc. Company Detail
11.14.2 Genentech, Inc. Business Overview
11.14.3 Genentech, Inc. Follicular Lymphoma Treatment Introduction
11.14.4 Genentech, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.14.5 Genentech, Inc. Recent Development
11.15 Gilead Sciences, Inc.
11.15.1 Gilead Sciences, Inc. Company Detail
11.15.2 Gilead Sciences, Inc. Business Overview
11.15.3 Gilead Sciences, Inc. Follicular Lymphoma Treatment Introduction
11.15.4 Gilead Sciences, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.15.5 Gilead Sciences, Inc. Recent Development
11.16 GlaxoSmithKline Plc
11.16.1 GlaxoSmithKline Plc Company Detail
11.16.2 GlaxoSmithKline Plc Business Overview
11.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Introduction
11.16.4 GlaxoSmithKline Plc Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.16.5 GlaxoSmithKline Plc Recent Development
11.17 Hutchison MediPharma Limited
11.17.1 Hutchison MediPharma Limited Company Detail
11.17.2 Hutchison MediPharma Limited Business Overview
11.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Introduction
11.17.4 Hutchison MediPharma Limited Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.17.5 Hutchison MediPharma Limited Recent Development
11.18 Immune Design Corp.
11.18.1 Immune Design Corp. Company Detail
11.18.2 Immune Design Corp. Business Overview
11.18.3 Immune Design Corp. Follicular Lymphoma Treatment Introduction
11.18.4 Immune Design Corp. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.18.5 Immune Design Corp. Recent Development
11.19 ImmunoGen, Inc.
11.19.1 ImmunoGen, Inc. Company Detail
11.19.2 ImmunoGen, Inc. Business Overview
11.19.3 ImmunoGen, Inc. Follicular Lymphoma Treatment Introduction
11.19.4 ImmunoGen, Inc. Revenue in Follicular Lymphoma Treatment Business (2019-2024)
11.19.5 ImmunoGen, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
